Plain-English translation of NCT05272696 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications: nab-paclitaxel, cisplatin, and pembrolizumab. These drugs are given together to try to shrink head and neck cancer before patients receive surgery or radiation therapy. The study wants to see how well this medication combination works and whether it helps patients avoid losing their voice or eating ability.
Head and neck cancer is a serious disease, and current treatments can sometimes damage important functions like speaking and swallowing. This trial is exploring whether this new treatment combination can shrink tumors more effectively, potentially reducing the need for extensive surgery or radiation that might harm these functions.
You likely qualify if…
You likely don't qualify if…
You would receive two rounds of the medication combination, with each round spaced three weeks apart. After these two treatment cycles, your doctors would evaluate how well the medication worked using imaging and team discussion. Depending on your response, you would then receive either surgery or radiation therapy (or both, if needed). The entire process typically takes several months, and you would have regular visits for blood tests, imaging scans, and check-ups with your medical team throughout.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Provincial People's Hospital
Enrollment target
~86 participants
Started
March 2022
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Haiqing Ma
Guangdong Provincial People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.